Roth Capital Comments on ICU Medical Inc.’s Q4 2017 Earnings (ICUI)
ICU Medical Inc. (NASDAQ:ICUI) – Stock analysts at Roth Capital cut their Q4 2017 earnings per share (EPS) estimates for shares of ICU Medical in a research report issued to clients and investors on Thursday. Roth Capital analyst C. Lewis now forecasts that the firm will post earnings per share of $1.05 for the quarter, down from their prior estimate of $1.10.
Several other research analysts also recently weighed in on ICUI. Piper Jaffray Cos. reissued a “neutral” rating and issued a $119.00 target price (up previously from $115.00) on shares of ICU Medical in a research note on Thursday, August 11th. Zacks Investment Research raised shares of ICU Medical from a “hold” rating to a “buy” rating and set a $140.00 target price for the company in a research note on Friday, August 12th.
Shares of ICU Medical (NASDAQ:ICUI) traded up 2.97% on Friday, reaching $148.98. 358,960 shares of the company were exchanged. The company has a 50-day moving average price of $125.42 and a 200 day moving average price of $112.09. The stock has a market capitalization of $2.40 billion, a PE ratio of 44.37 and a beta of 0.37. ICU Medical has a 1-year low of $85.56 and a 1-year high of $149.21.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/07/roth-capital-comments-on-icu-medical-inc-s-q4-2017-earnings-icui.html
ICU Medical (NASDAQ:ICUI) last posted its quarterly earnings data on Monday, August 8th. The company reported $1.15 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.05 by $0.10. ICU Medical had a net margin of 14.94% and a return on equity of 10.33%. The business earned $96.70 million during the quarter, compared to analyst estimates of $89.66 million. During the same quarter last year, the firm posted $0.97 earnings per share. The business’s revenue for the quarter was up 15.4% compared to the same quarter last year.
In other news, VP Thomas D. Mccall sold 2,071 shares of the company’s stock in a transaction dated Thursday, August 11th. The shares were sold at an average price of $126.07, for a total transaction of $261,090.97. Following the completion of the transaction, the vice president now owns 2,129 shares of the company’s stock, valued at approximately $268,403.03. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Richard Md Sherman sold 3,000 shares of the company’s stock in a transaction dated Monday, September 19th. The shares were sold at an average price of $122.51, for a total transaction of $367,530.00. Following the transaction, the director now directly owns 70,699 shares of the company’s stock, valued at approximately $8,661,334.49. The disclosure for this sale can be found here. Insiders own 15.90% of the company’s stock.
Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Silvercrest Asset Management Group LLC increased its position in ICU Medical by 14.8% in the first quarter. Silvercrest Asset Management Group LLC now owns 512,923 shares of the company’s stock worth $53,396,000 after buying an additional 65,978 shares in the last quarter. Eqis Capital Management Inc. increased its position in ICU Medical by 0.7% in the second quarter. Eqis Capital Management Inc. now owns 2,509 shares of the company’s stock worth $283,000 after buying an additional 18 shares in the last quarter. Jacobs Levy Equity Management Inc. increased its position in ICU Medical by 527.4% in the first quarter. Jacobs Levy Equity Management Inc. now owns 37,270 shares of the company’s stock worth $3,880,000 after buying an additional 31,330 shares in the last quarter. Bayesian Capital Management LP increased its position in ICU Medical by 0.3% in the first quarter. Bayesian Capital Management LP now owns 2,150 shares of the company’s stock worth $224,000 after buying an additional 7 shares in the last quarter. Finally, Hancock Holding Co. increased its position in ICU Medical by 20.4% in the first quarter. Hancock Holding Co. now owns 8,550 shares of the company’s stock worth $890,000 after buying an additional 1,450 shares in the last quarter. 89.50% of the stock is owned by institutional investors.
About ICU Medical
ICU Medical, Inc is engaged in the development, manufacturing and sales of medical devices used in infusion therapy, oncology and critical care applications. The Company’s product line includes needlefree connection devices, closed system transfer devices (CSTD), needlefree closed blood sampling systems, disposable pressure transducer systems and hemodynamic monitoring systems.
Receive News & Ratings for ICU Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ICU Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.